Trial Profile
A lead-in Phase I Followed by a Phase II Clinical Trial on the Combination of Dabrafenib, Trametinib and the Autophagy Inhibitor Hydroxychloroquine in BRAF/MEK Inhibitor-pretreated Patients With Advanced BRAF V600 Mutant Melanoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Hydroxychloroquine (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms COMBI-R2
- 01 Jun 2022 Status changed from recruiting to discontinued.
- 01 Jun 2022 Results published in the Melanoma Research
- 27 Apr 2021 Planned End Date changed from 1 Dec 2020 to 1 Jul 2022.